Cerus Beats EPS, Raises Guidance as Shares Jump 13% After Q1 2026 Beat
Cerus Corporation (NASDAQ:CERS) posted a first‑quarter 2026 GAAP EPS of -$0.01, beating the consensus estimate of -$0.03, while revenue came in at $59.9 million, topping the $55.7 million forecast. The results sent the stock up 13.05% in after‑hours trading to $2.29 from $2.03.
Earnings Summary
Cerus reported GAAP earnings per share of -$0.01, a $0.02 beat versus analysts’ expectations of -$0.03. Revenue reached $59.9 million, up 23% YoY and $4.2 million above the consensus estimate of $55.7 million. Gross margin slipped to 52.0% from 58.8% a year ago, reflecting inflationary cost pressures and foreign‑currency headwinds. Net loss narrowed dramatically to $1.6 million (or $0.01 per share) from $7.7 million a year earlier.
Guidance & Outlook
Management raised full‑year product revenue guidance to $227 million‑$231 million, reflecting a 10%‑12% YoY increase and the strong momentum of the INTERCEPT Fibrinogen Complex (IFC). The company highlighted several upcoming catalysts: a European regulatory review of INTERCEPT RBC, the Phase 3 RedeS readout in the U.S., and a planned U.S. PMA submission for the new INT200 illumination device.
Conference Call Highlights
- CEO Obi Greenman emphasized “a strong start to 2026” driven by “increasing demand for our INTERCEPT Fibrinogen Complex.”
- The company announced a four‑year supply agreement with Établissement Français du Sang (EFS) covering both the INTERCEPT Blood System and the INT200 device.
- Vivek Jayaraman will assume the role of President and CEO on July 1, 2026, with Greenman transitioning to Executive Chairman.
- Operating expenses fell 7% YoY to $34.5 million, with R&D down 12% as the INT200 program moves toward the PMA filing.
Market Reaction & Analyst Commentary
The after‑hours price surge to $2.29 (+13.05%) reflected investor enthusiasm for the revenue beat and the upgraded guidance. QuiverQuant reported that the stock “rose on Q1 2026 earnings” after analysts highlighted the 22.6% YoY revenue growth and the beat of consensus estimates. MarketBeat echoed the sentiment, noting the revenue beat of $59.9 million versus the $54.2 million consensus and the EPS beat.
Analysts at Yahoo Finance upgraded several price targets, citing the “accelerating international momentum” and the “meaningful catalyst path” outlined in the call. The consensus price target rose to roughly $2.45, implying modest upside from the current after‑hours level.
Investor Takeaways
Cerus delivered a solid top‑line beat, narrowed losses, and lifted its full‑year product revenue outlook, all while announcing a strategic French supply contract and a leadership transition. The combination of strong IFC demand, upcoming regulatory milestones, and a tighter cost structure underpins the bullish sentiment reflected in the 13% after‑hours rally.
Looking ahead, investors will watch the Phase 3 RedeS readout, the EU INTERCEPT RBC review, and the INT200 PMA filing as the primary drivers of future price action.
Key Takeaways
- Q1 2026 GAAP EPS of -$0.01 beats consensus by $0.02; revenue of $59.9 M beats estimate by $4.2 M.
- Full‑year product revenue guidance raised to $227‑$231 M, driven by strong IFC demand.
- After‑hours stock jumps 13% to $2.29, with analysts upgrading price targets to ~$2.45.
- Upcoming catalysts include EU regulatory review, Phase 3 RedeS readout, and INT200 PMA submission.
- Leadership change announced: Vivek Jayaraman to become President & CEO on July 1, 2026.